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Introduction
Acquired inhibitors to Factor VIII in nonhaemophil-
iac patients are rare, but serious, having an incidence
of 1–4 million)1 year)1 [1,2]. These inhibitors are
autoantibodies, usually IgG and polyclonal in nature.
The majority occur in older people, with a median
age at presentation of 60–67 [1,3,4], although they
may also occur during pregnancy and in the post-
partum period. Fifty percent of cases have identifi-
able associated conditions, including pregnancy,
malignancy and autoimmune disease. Serious bleed-
ing occurs in up to 87% of cases and between 13 and
22% die due to uncontrolled haemorrhage, usually
within a few weeks of presentation [4,5].
Treatment consists of immunosuppression, most
commonly using steroid to suppress the inhibitor, and
factor replacement to control haemorrhage if appro-
priate. Prednisolone 1 mg kg)1 day)1 suppresses
around 30% of acquired inhibitors, and a response
will usually be seen within 3–6 weeks [4,6,7]. A
response rate of 30% has also been reported for
intravenous immunoglobulin (IVIg) alone. This is
thought to be an anti-idiotypic effect with responses
seen within 5 days [8]. Combination therapy with
prednisolone and cyclophosphamide produces res-
ponses in 60–70% [7,9]. Other immunosuppressive
regimens have varying success [10–12]. Likelihood of
response to treatment cannot be predicted from
clinical parameters, although in pregnancy-related
inhibitors, spontaneous remission is likely.
The use of prednisolone and IVIg together is
appealing, as the combination may produce a more
rapid response than either agent alone, without the
toxicity seen in more immunosuppressive regimens.
There are few published reports of this combination
but it is recommended as first-line therapy in some
countries [13]. We report here on 2 years’ experience
of initial treatment of acquired FVIII inhibitors using
a standard regimen of prednisolone 1 mg kg)1 day)1
and IVIg 2 g kg)1 in divided doses.
Patient details & laboratory evaluation
Between June 1998 and June 2000 seven patients
with newly diagnosed acquired inhibitors of FVIII
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were treated. There were four males and three
females, with a median age of 77 years (65 years –
83 years). Four of the patients gave a history of
minor bleeding over the preceding weeks to months.
All patients had active bleeding and a prolonged
activated partial thromboplastin time (APTT) at the
time of presentation.
FVIII activity was measured with a one-stage
APTT based system using FVIII-deficient plasma
(Diagen, Oxon, UK). Where results were nonlinear,
the FVIII level was taken from the 1 : 5 dilution.
The FVIII inhibitor assay was carried out according
to the Bethesda method [14] without the Nijmegen
modification. IgG and IgM anticardiolipin antibodies
(ACA) were measured by ELISA (Cambridge Life
Sciences, Cambridge, UK) and functional lupus
inhibitor studies were performed (dilute Russell
Viper Venom Test (dRVVT); Diagen), with confirm-
atory testing by platelet neutralization.
Therapy
All patients received standardized treatment with
prednisolone 1 mg kg)1 day)1 and IVIg 2 g kg)1.
The IVIg was initially divided into two daily doses
(patients 2 and 5) but later given over 5 days to
reduce the risk of developing acute renal impairment
[15]. Prednisolone was given at 1 mg kg)1 for
2 weeks then tapered. Blood products were admin-
istered based on clinical judgement of severity of
bleeding.
Criteria for assessing response to therapy were
those defined by Spero et al. A complete response
(CR) was defined as disappearance of the inhibitor,
improvement of the FVIII activity to greater than
50 IU dL)1 and cessation of bleeding. A partial
response (PR) involved a decrease of inhibitor titre of
greater than 75%, improvement in the FVIII activity
to less than 50 IU dL and/or improvement in haem-
orrhagic signs. No response (NR) was a failure to
improve or worsening of laboratory and/or clinical
findings after at least 14 days of treatment [6].
Results
Table 11 summarizes the main clinical and laboratory
details and outcomes of the seven patients. One
patient with recurrent squamous cell carcinoma died
within 3 months of diagnosis of the inhibitor.
Response to treatment in this patient could not be
assessed as he was discharged to terminal care after
12 days, at which time there was no improvement in
FVIII activity. All other patients are surviving with
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no evidence of bleeding, with a median follow-up
time of 10.5 months (3–24 months).
FVIII activity at diagnosis was < 10 IU dL)1 in all
but one case (patient 3, 21 IU dL)1). Inhibitor levels
at diagnosis ranged from 1 to 77 Bethesda units (BU),
with four being above 10 BU. Three patients
(patients 1, 2 & 4) had raised anticardiolipin
antibodies (ACA) at diagnosis, two had raised IgM
levels (20 and > 120 U mL)1; normal 0–5 U mL)1)
and two had raised IgG (12 and 15.6 U mL)1;
normal 0–9 U mL)1). Patient 7 was positive for
lupus anticoagulant. In all other patients this test was
normal.
Response to IVIg and prednisolone
Serial FVIII activities and inhibitor levels for all
patients are shown in Fig. 1. Four patients attained
CR, with a rapid reduction of inhibitor titres, all
being undetectable by day 21 (median 5.5 days).
Transfusion-independent FVIII activity of > 20 IU
dL)1 was reached at a median of 14 days (range
5–35 days), and > 50 IU dL)1 at a median of
31 days (8–150 days). One patient (patient 6)
attained a PR; the inhibitor level became undetect-
able and the FVIII activity rose to > 20 IU dL)1 by
day 28, but the FVIII failed to normalize despite the
subsequent addition of cyclophosphamide. There
was one nonresponder (patient 1) who presented
with life-threatening tracheal compression requiring
tracheostomy because of a spontaneous haematoma
and an inhibitor level of 54 BU, subsequently rising
to 205 BU. Only after 9 months and additional
cyclophosphamide did the inhibitor titre become
undetectable. FVIII activity remained poor, ranging
between 8 IU dL)1 and 40 IU dL)1 18 months after
diagnosis.
Six of the seven patients were noted to have
significant bleeding at the time of diagnosis. Five
were treated with FVIII concentrate and four with
prothrombin complex concentrate (three were given
both).
One patient (patient 2) relapsed 2 months after
diagnosis as the prednisolone dose was tapered, but
responded to increased prednisolone and the addi-
tion of cyclophosphamide. Of the four patients who
attained CR (including the second remission in
patient 2), normal FVIII activity has been maintained
without treatment for 2–8 months.
Discussion
Over a period of 2 years, our institution has treated
seven patients with acquired inhibitors to FVIII. An
eighth case was treated locally. Thus, the annual
incidence in this area (covering approx 2.5 million) is
1.8 million)1, a figure in keeping with other esti-
mates [1]. Although several patients had pre-existing
illnesses such as diabetes and ischaemic heart disease,
these may simply reflect the age of the population.
Two patients had malignancy related to the forma-
tion of their inhibitor. Thus underlying pathology
was established in only 29% of cases, which is less
than the often quoted 50%, but similar to that found
by others [12].
Although there is good evidence that some inhib-
itors remit spontaneously, this occurs in less than
one-third of patients [1], partially treated patients
remain at risk of haemorrhage-related death [6].
Therefore, effective suppression of inhibitor with
normalization of FVIII levels is the goal of treatment.
Treatment regimens must be suitable for the patients,
who are typically elderly, often with multiple coex-
isting diseases. Prednisolone is well tolerated and
IVIg-related renal impairment can be avoided by
dividing the dose over 5 days.
The overall response rate for IVIg and predniso-
lone as primary therapy in this series is 5/7 (71%).
Fig. 1. (A,B). FVIII activity and inhibitor levels for all patients
over the first 12 weeks from diagnosis. Inhibitor levels are shown
on a logarithmic scale. Inhibitor levels below the level of detection
are arbitrarily shown as 0.3 BU.
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This is better than for prednisolone or IVIg alone
(each around 30%) [6,8], but is similar to that
reported for cyclophosphamide plus prednisolone
[4,7]. Lian et al. used combination chemotherapy
(cyclophosphamide, vincristine, prednisolone) with
FVIII concentrate infusion successfully in 11/12
patients, who required between one and three
courses to achieve prolonged remissions [11]. How-
ever, this impressive result was at the cost of
significant neutropenic side-effects, and we feel this
regimen is too toxic as a first-line therapy.
There was a rapid drop in inhibitor level in the
responding patients, becoming undetectable by day
21 in all CRs, and by day 28 in the one PR. FVIII
activity was slightly slower to reach normal (median
31 days). It is difficult to make accurate comparisons
of time to response for alternative therapeutic
regimens, although response times in our cohort are
certainly shorter than some [10–12,16], particularly
for suppression of the inhibitor [7]. This may be
important in the prevention of early haemorrhagic
deaths.
Response to treatment was not related to patient
age or gender, nor to the presence or absence of
underlying malignancy. Inhibitor level at diagnosis
did not act as a guide to response, as suggested by
some investigators [9], and in fact the case with the
highest initial inhibitor level achieved CR.
We have found that the combination of predniso-
lone 1 mg kg)1 day)1 with IVIg 2 g kg)1 in divided
doses, in conjunction with active factor replacement
for bleeding, is a successful approach to the suppres-
sion of acquired inhibitors. However, it is not
possible to assess effectiveness of this regimen in the
treatment of pregnancy or auto-immune associated
acquired inhibitors as neither group was represented
in our patient cohort. This treatment protocol is easy
to administer, well-tolerated, and can be started with
little delay at the time of diagnosis. The regimen
produces a good response rate, and the speed of
response, particularly the reduction in inhibitor
level, is rapid, perhaps helping to prevent early
haemorrhagic deaths.
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